

# ESMO PRECEPTORSHIP PROGRAMME COLORECTAL CANCER

Multidisciplinary management, standards of care  
and future perspectives

Valencia, Spain  
12-13 May 2017

**CO-CHAIRS:** Andrés Cervantes, Spain  
Dirk Arnold, Portugal

**SPEAKERS:** Regina Beets-Tan, Netherlands (TBC)  
Frédéric Bibeau, France  
Chiara Cremolini, Italy  
Michel Ducreux, France  
Robert Glynne-Jones, United Kingdom  
Clara Montagut, Spain  
Pompiliu Piso, Germany  
Hans-Rudolf Raab, Germany

## LEARNING OBJECTIVES

- To learn about best clinical practice in the multidisciplinary management of colorectal cancer in the adjuvant and metastatic settings
- To understand the importance of pathology and histoprognostic factors
- To learn about the management of patients after progression, side-effects of treatments and in special situations

### Friday, 12 May 2017

<b>09:00-9:15</b> 15'	<b>Welcome and introduction</b>	<b>Andrés Cervantes, ES</b>
<b>09:15-10:50</b> 95'	<b>Session 1</b> <b>Early colorectal cancer</b>	<b>Chair:</b> <b>Pompiliu Piso, DE</b>
30'	The point of view of the pathologist - Quality and rules of a good pathology report - Histo-prognostic factors: Number of Lymph nodes, neural/lymphatic invasion, lymphocytic infiltration, MSH expression	Frédéric Bibeau, FR
20'	State-of-the-art: Standard of surgical practice for resectable colorectal cancer (special issues on rectal cancer)	Hans-Rudolf Raab, DE
25'	State-of-the-art: Standard(s) of local treatments (radio-/chemotherapy) for rectal cancer	Robert Glynne-Jones, UK
20'	The role of chemotherapy of rectal cancer	Andrés Cervantes, ES
<b>10:50-11:20</b>	<b>Coffee Break</b>	

<b>11:20-13:25 125'</b>	<b>Session 2 Metastatic colorectal cancer, liver limited metastases</b>	<b>Chair : Andrés Cervantes, ES</b>
20'	Review of the ESMO consensus conference on metastatic colorectal cancer - Basic strategies and groups (RASwt /mut, BRAF mut)	Chiara Cremolini, IT
45'	Presentation of three challenging clinical cases and faculty discussion	Andrés Cervantes, ES All Faculty
30'	Treating Oligometastatic colorectal cancer	Dirk Arnold, PT
3x10'	3 x Participant clinical case discussion	All Faculty

<b>13:25-14:25</b>	<b>Lunch</b>
--------------------	--------------

<b>14:25-16:25 120'</b>	<b>Session 3 Adjuvant settings of colorectal cancer</b>	<b>Chair : Dirk Arnold, PT</b>
30'	Microsatellite instability and other molecular markers – how useful are they?	Frédéric Bibeau, FR
30'	Adjuvant treatment for colon cancer II and III	Michel Ducreux, FR
30'	Imaging for staging colorectal cancer: localized and advanced	Regina Beets-Tan, NL
3x10'	3 x Participant clinical case discussion	All Faculty

<b>16:25-16:55</b>	<b>Coffee Break</b>
--------------------	---------------------

<b>16:55-18:25 90'</b>	<b>Session 4 Metastatic colorectal cancer: special clinical situations</b>	<b>Chair: Andrés Cervantes, ES</b>
20'	Treatment of metastatic disease confined to the peritoneum - Resection - HIPEC - PIPEC	Pompiliu Piso, DE
20'	Primary with synchronous metastases	Hans-Rudolf Raab, DE
20'	Chemotherapy and targeted agents in 1 <sup>st</sup> line	Chiara Cremolini, IT
30'	<u>SPECIAL LECTURE</u> The role of liquid biopsies in the treatment of advanced colon cancer	Clara Montagut, ES

<b>19:30</b>	<b>Dinner</b>
--------------	---------------

## Saturday, 13 May 2017

<b>08:30- 10:00 90'</b>	<b>Session 5 Metastatic colorectal cancer : Maintenance and further lines</b>	<b>Chair: Dirk Arnold, PT</b>
30'	The role of maintenance, appropriate endpoints according to ESMO consensus	Michel Ducreux, FR
30'	What to do after 1 <sup>st</sup> line failure	Dirk Arnold, PT
30'	Management of treatment related side effects - GI-Toxicity - Neuropathy - Skin toxicity - Hypertension - Hand-foot syndrome	Michel Ducreux, FR

<b>10:00-10:30</b>	<b>Coffee Break</b>
--------------------	---------------------

<b>10:30-11:00</b> <b>30'</b>	<b>Session 6</b> <b>Metastatic colorectal cancer : Case discussion</b>	<b>Chair:</b> <b>Andrés Cervantes, ES</b>
3x10'	3 x Participant clinical case discussion	All Faculty
<b>11:00-11:45</b> <b>45'</b>	<b>Session 7</b> <b>Anal Canal tumours</b>	<b>Chair:</b> <b>Pompiliu Piso, DE</b>
30'	Standard of care for Anal Canal Squamous carcinomas	Robert Glynn-Jones, UK
15'	Salvage surgery of Anal Canal Squamous carcinomas	Pompiliu Piso, DE
<b>11:45-12:00</b> <b>15'</b>	<b>Conclusion and farewell</b>	<b>Chair:</b> <b>Andrés Cervantes, ES</b>
12:00	Lunch	

**Note:** Each 10 minute slot for clinical case discussion includes 5' case presentation and 5' Q&A / panel discussion